Applied Therapeutics, Inc. (NASDAQ:APLT) Shares Acquired by Marshall Wace LLP

Marshall Wace LLP lifted its stake in shares of Applied Therapeutics, Inc. (NASDAQ:APLT - Free Report) by 144.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,307,381 shares of the company's stock after purchasing an additional 773,377 shares during the quarter. Marshall Wace LLP owned about 1.12% of Applied Therapeutics worth $1,124,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. XTX Topco Ltd raised its stake in shares of Applied Therapeutics by 178.0% during the fourth quarter. XTX Topco Ltd now owns 173,568 shares of the company's stock worth $149,000 after purchasing an additional 111,128 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Applied Therapeutics by 293.9% during the fourth quarter. Legal & General Group Plc now owns 84,018 shares of the company's stock worth $72,000 after purchasing an additional 62,686 shares during the last quarter. Aristides Capital LLC purchased a new stake in shares of Applied Therapeutics during the fourth quarter worth approximately $134,000. Wellington Management Group LLP raised its stake in shares of Applied Therapeutics by 17.8% during the fourth quarter. Wellington Management Group LLP now owns 237,850 shares of the company's stock worth $204,000 after purchasing an additional 35,884 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Applied Therapeutics during the fourth quarter worth approximately $208,000. Hedge funds and other institutional investors own 98.31% of the company's stock.

Applied Therapeutics Price Performance

Applied Therapeutics stock opened at $0.39 on Wednesday. The business has a 50 day simple moving average of $0.45 and a 200-day simple moving average of $2.67. The stock has a market capitalization of $55.58 million, a PE ratio of -0.24 and a beta of 1.88. Applied Therapeutics, Inc. has a 12 month low of $0.30 and a 12 month high of $10.62.

Applied Therapeutics (NASDAQ:APLT - Get Free Report) last released its quarterly earnings data on Monday, April 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.06). The business had revenue of $0.00 million during the quarter, compared to analysts' expectations of $0.61 million. As a group, equities research analysts anticipate that Applied Therapeutics, Inc. will post -0.65 EPS for the current year.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.

Want to see what other hedge funds are holding APLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Applied Therapeutics, Inc. (NASDAQ:APLT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.